Glaxosmithkline Plc Adr Stock Buy Hold or Sell Recommendation
| GSK Stock | USD 39.27 0.33 0.83% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding GlaxoSmithKline PLC ADR is 'Hold'. Macroaxis provides GlaxoSmithKline PLC buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GSK positions. The advice algorithm takes into account all of GlaxoSmithKline PLC's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting GlaxoSmithKline PLC's buy or sell advice are summarized below:
Real Value 40.15 | Target Price 39.63 | Hype Value 39.27 | Market Value 39.27 | Naive Value 39.09 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell GlaxoSmithKline PLC ADR given historical horizon and risk tolerance towards GlaxoSmithKline PLC. When Macroaxis issues a 'buy' or 'sell' recommendation for GlaxoSmithKline PLC ADR, the advice is generated through an automated system that utilizes algorithms and statistical models.
GlaxoSmithKline |
Execute GlaxoSmithKline PLC Buy or Sell Advice
The GlaxoSmithKline recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on GlaxoSmithKline PLC ADR. Macroaxis does not own or have any residual interests in GlaxoSmithKline PLC ADR or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute GlaxoSmithKline PLC's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
GlaxoSmithKline PLC Trading Alerts and Improvement Suggestions
| On 11th of April 2024 GlaxoSmithKline PLC paid $ 0.4061 per share dividend to its current shareholders | |
| Latest headline from benzinga.com: Once Valued At Billions, 23andMes CEO Considers Privatization To Secure Companys Future |
GlaxoSmithKline PLC Returns Distribution Density
The distribution of GlaxoSmithKline PLC's historical returns is an attempt to chart the uncertainty of GlaxoSmithKline PLC's future price movements. The chart of the probability distribution of GlaxoSmithKline PLC daily returns describes the distribution of returns around its average expected value. We use GlaxoSmithKline PLC ADR price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of GlaxoSmithKline PLC returns is essential to provide solid investment advice for GlaxoSmithKline PLC.
| Mean Return | -0.0043 | Value At Risk | -1.49 | Potential Upside | 1.52 | Standard Deviation | 0.92 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of GlaxoSmithKline PLC historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
GlaxoSmithKline Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlaxoSmithKline PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlaxoSmithKline PLC ADR backward and forwards among themselves. GlaxoSmithKline PLC's institutional investor refers to the entity that pools money to purchase GlaxoSmithKline PLC's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Arrowstreet Capital Limited Partnership | 2023-12-31 | 4.8 M | Mondrian Investment Partners Ltd | 2023-12-31 | 4 M | Provident Trust Company | 2023-12-31 | 3.7 M | Equity Investment Corp | 2023-12-31 | 3.2 M | Eversept Partners, Llc | 2023-12-31 | 3 M | Renaissance Technologies Corp | 2023-12-31 | 2.8 M | Hotchkis & Wiley Capital Management Llc | 2023-12-31 | 2.7 M | Hsbc Holdings Plc | 2023-12-31 | 2.5 M | Wells Fargo & Co | 2023-12-31 | 2.5 M | Dodge & Cox | 2023-12-31 | 69 M | Fmr Inc | 2023-12-31 | 19.4 M |
GlaxoSmithKline PLC Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 300M | 119M | 25M | (269M) | (424M) | (402.8M) | |
| Change In Cash | 744M | 431M | (1.4B) | (394M) | (787M) | (747.7M) | |
| Free Cash Flow | 5.9B | 6.2B | 5.0B | 5.1B | 4.0B | 3.4B | |
| Depreciation | 3.0B | 624M | 2.5B | 2.3B | 2.3B | 1.4B | |
| Other Non Cash Items | 814M | 848M | 756M | (433M) | 540M | 567M | |
| Capital Expenditures | 2.2B | 2.2B | 2.9B | 2.3B | 2.3B | 1.5B | |
| Net Income | 5.3B | 6.4B | 5.1B | 4.9B | 4.9B | 4.6B | |
| End Period Cash Flow | 4.8B | 5.3B | 3.8B | 3.4B | 2.9B | 2.1B | |
| Dividends Paid | 4.0B | 4.0B | 4.0B | 3.5B | (2.2B) | (2.1B) | |
| Investments | (5.4B) | 2.2B | 334M | (8.8B) | (1.6B) | (1.5B) | |
| Net Borrowings | 3.5B | (4.2B) | (2.2B) | (4.8B) | (5.5B) | (5.8B) | |
| Change To Netincome | 670M | 380M | 105M | (8.3B) | (9.6B) | (10.1B) |
GlaxoSmithKline PLC Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to GlaxoSmithKline PLC or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that GlaxoSmithKline PLC's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a GlaxoSmithKline stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.04 | |
β | Beta against NYSE Composite | 0.46 | |
σ | Overall volatility | 0.93 | |
Ir | Information ratio | -0.08 |
GlaxoSmithKline PLC Volatility Alert
GlaxoSmithKline PLC ADR exhibits very low volatility with skewness of 0.52 and kurtosis of 1.53. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure GlaxoSmithKline PLC's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact GlaxoSmithKline PLC's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.GlaxoSmithKline PLC Implied Volatility
GlaxoSmithKline PLC's implied volatility exposes the market's sentiment of GlaxoSmithKline PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if GlaxoSmithKline PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that GlaxoSmithKline PLC stock will not fluctuate a lot when GlaxoSmithKline PLC's options are near their expiration.
GlaxoSmithKline PLC Fundamentals Vs Peers
Comparing GlaxoSmithKline PLC's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze GlaxoSmithKline PLC's direct or indirect competition across all of the common fundamentals between GlaxoSmithKline PLC and the related equities. This way, we can detect undervalued stocks with similar characteristics as GlaxoSmithKline PLC or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of GlaxoSmithKline PLC's fundamental indicators could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare GlaxoSmithKline PLC to competition |
| Fundamentals | GlaxoSmithKline PLC | Peer Average |
| Return On Equity | 0.46 | -0.31 |
| Return On Asset | 0.0881 | -0.14 |
| Profit Margin | 0.16 % | (1.27) % |
| Operating Margin | 0.20 % | (5.51) % |
| Current Valuation | 172.41 B | 16.62 B |
| Shares Outstanding | 2.04 B | 571.82 M |
| Shares Owned By Institutions | 14.42 % | 39.21 % |
| Number Of Shares Shorted | 4.83 M | 4.71 M |
| Price To Earning | 11.80 X | 28.72 X |
| Price To Book | 4.96 X | 9.51 X |
| Price To Sales | 2.75 X | 11.42 X |
| Revenue | 30.33 B | 9.43 B |
| Gross Profit | 19.92 B | 27.38 B |
| EBITDA | 9.29 B | 3.9 B |
| Net Income | 4.93 B | 570.98 M |
| Cash And Equivalents | 3.72 B | 2.7 B |
| Cash Per Share | 0.32 X | 5.01 X |
| Total Debt | 18.02 B | 5.32 B |
| Debt To Equity | 0.98 % | 48.70 % |
| Current Ratio | 1.43 X | 2.16 X |
| Book Value Per Share | 3.29 X | 1.93 K |
| Cash Flow From Operations | 6.35 B | 971.22 M |
| Short Ratio | 1.83 X | 4.00 X |
| Earnings Per Share | 2.99 X | 3.12 X |
| Price To Earnings To Growth | 1.09 X | 4.89 X |
| Target Price | 45.32 | |
| Number Of Employees | 70.21 K | 18.84 K |
| Beta | 0.27 | -0.15 |
| Market Capitalization | 81.18 B | 19.03 B |
| Total Asset | 59.01 B | 29.47 B |
| Retained Earnings | 7.24 B | 9.33 B |
| Working Capital | (2.42 B) | 1.48 B |
| Current Asset | 16.59 B | 9.34 B |
GlaxoSmithKline PLC Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as GlaxoSmithKline . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About GlaxoSmithKline PLC Buy or Sell Advice
When is the right time to buy or sell GlaxoSmithKline PLC ADR? Buying financial instruments such as GlaxoSmithKline Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 24.2B | 21.0B | 18.0B | 11.0B | Total Assets | 79.1B | 60.1B | 59.0B | 32.8B |
Use Investing Ideas to Build Portfolios
In addition to having GlaxoSmithKline PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Compulsion Thematic Idea Now
Compulsion
Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. The Compulsion theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Compulsion Theme or any other thematic opportunities.
| View All Next | Launch |
Check out GlaxoSmithKline PLC Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Dividend Share 0.58 | Earnings Share 2.99 | Revenue Per Share 14.97 | Quarterly Revenue Growth 0.092 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.